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Abstract
Although the potential of vibrational spectroscopy for biomedical applications has been well
demonstrated, translation into clinical practice has been relatively slow. This perspective
assesses the challenges facing the field and the potential way forward. While many
technological challenges have been addressed to date, considerable effort is still required to
gain acceptance of the techniques among the medical community, standardize protocols,
extend to clinically relevant scale, and ultimately assess the health economics underlying
clinical deployment. National and international research networks can contribute much to
technology development and standardization. Ultimately, large-scale funding is required to
engage in clinical trials and instrument development.

Keywords: Vibrational Spectroscopy, Raman Spectroscopy, Infrared spectroscopy,
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Introduction
Disease diagnostics have long relied on visual differences in tissue appearance, aided in
modern histopathology and cytology by optical stains and microscopic technologies.
However, such approaches are based on changes in tissue and cell morphology, often
apparent only at the later stages of disease development, rather than the underlying
biochemical changes associated with disease onset or aetiology. Optical techniques for
routine screening are particularly suitable for more accessible anatomical sites such as
mouth and throat, skin and cervix, but although optical techniques such as colposcopy for
cervical or conventional oral examination for oral cancer are routinely used, they have low
sensitivity and specificity. They rely on the trained eye of a clinical specialist, and consensus
between such specialists can be low, particularly in the early stages of disease onset [1].
Spectroscopic techniques are based on changes in underlying biochemical structure and
therefore potentially offer a more objective analysis, which is therefore automatable and
adaptable to routine screening. In this context, fluorescence spectroscopic techniques have
received considerable attention, although, for a label free technology, analysis is based only
on endogenous fluorophores such as collagen, elastin, keratin, riboflavin porphyrin and
NADH. Emission bands are broad and overlapping, reducing the specificities of such
techniques. The use of UV excitation also limits the sampling depth in tissue. As an
alternative, vibrational spectroscopy, both infrared absorption and Raman scattering, offers
many potential advantages, as it provides a spectroscopic signature of all molecular
constituents of the sample, and as such a complex fingerprint which can be used to uniquely
identify a compound, collection of compounds, or subtle changes to it or them.

The potential of vibrational spectroscopy for biomedical applications has been well
established through many proof of concept studies over the past decades [2-5]. Due to its
unique fingerprinting capability, vibrational spectroscopy can play a significant role in
histopathology, cytology, biopsy targeting, surgical targets, treatment monitoring and drug
studies. Application scenarios could include single shot measurement of targeted nuclei for
cytological screening, or in imaging and/or mapping larger areas for diagnostics or high
content analysis, in vivo, ex vivo or in vitro. However, translation into the clinical
environment has been slow, and it is appropriate at this stage to assess and evaluate
questions such as (i) What are the most achievable, strategic target applications, (ii) What
are the technical challenges, and how can they be addressed (iii) What are the challenges to
implementation (legislative, clinical trials etc.), and how can they be addressed. This
perspective considers such questions under the subheadings of (i) Translational research
into in vivo clinical applications (ii) Ex vivo tissue biopsies, body fluids and cytological
samples for diagnostics and disease studies (iii) In vitro cell culture and 3D models for
Research and Medical applications.
(i) Translational research into in vivo clinical applications
As an optical based technology, vibrational spectroscopy is easily adaptable to in vivo
disease diagnostics and monitoring applications, ranging from intraoperative assessment of
auxiliary lymph nodes using Raman spectroscopy [6] to IR photoacoustic dermal screening
[7]. Significant development of Raman fibre probes for in vivo diagnostics and intraoperative
patient monitoring has been achieved in recent years [8]. In the latter context, identification
of tumour margins has been highlighted as a potentially a significant aid to surgeons. This
has been shown in various forms using fibres or microscope based approaches.

FTIR probes for surface analysis and or evanescent wave analysis of fluids are available [9],
although these are clearly limited if lesions of interest are to be found more than a few
microns below the surface.
Skin is the most accessible organ and therefore should be a strategic target. In addition to
diagnostic applications [10], spectroscopy could provide significant guidance for monitoring
and optimising transdermal drug delivery [11], as well as understanding dermal toxicity from
external agents such as nanoparticles, chemicals and radiation [12].
The question should therefore be posed, in terms of In vivo clinical applications – Is the
vision right? If the performance of the technology is optimised, and applications
demonstrated with appropriate large scale studies, will there be uptake in a clinical
environment? There is a need to balance the drive for technology development from the
research community with the needs of the clinical environment. Are there technological
solutions looking for a problem or clinical problems looking for a solution?
In this context, it is important to engage with the medical community to establish firstly the
demand for the technological solutions, and secondly, what is the Minimal Viable Solution.
Researchers strive for both fast acquisition rates and high quality spectral data, but in a
surgical environment, time is of the essence, and so a fast, simple spectroscopic modality,
which is cheaper, more cost effective but has lower sensitivity and specificity may be a
viable solution. This poses the question as to how much of a compromise can be made in
terms of performance. While values approaching 100% have been quoted for laboratory
based studies, is 80% sensitivity/ specificity sufficient in a clinical setting? The required
performance levels will depend on the specific application, (Tissue type, screening/biopsy
targeting/margin assessment) and therefore it is difficult to establish a generic Minimal

Viable Solution. It is, however, crucial to establish what the realistic and actual current gold
standard performance is for a number of specific strategic applications such that
spectroscopic performance can be directly compared and evaluated with these reference
diagnostic techniques. Realistic evaluations and comparisons of variability and costs are also
imperative. This is something that was demonstrated by providing Kappa statistics of the
performance of the technique versus a panel of expert pathologists [1].
Most research studies to date have been conducted on general purpose research
instruments and there is a need to develop and optimise commercial products to be trialled
and validated. In this context, reproducibility of systems is a vital technical challenge to be
addressed, as is transferability of datasets between systems. There is currently a huge gap
between the research community and commercial/industrial partners. Big medical
diagnostic companies need to be on board and engaged in the drive towards strategic and
targeted technological development.
Critically, while the research environment has demands on demonstrating reproducibility of
data, the demands of clinical deployment are substantially more rigorous. Studies must
therefore be extended to use of clinically appropriate scale and statistical analysis, to be
considered meaningful. The statistical and ethical plan needs to be outlined for each study,
which should include significant sample sizes (~150 patients) and blind datasets, while
outcomes should detail sensitivity, specificity, AUC etc.
To date, the proof of concept has been adequately demonstrated, but there is a need to
develop large (randomised controlled) clinical trials for the technology to be adopted by the
clinical community. However, such trails carry considerable cost implications, taking into

account implementation costs and the cost of developing further studies; the cost of
(randomized) clinical trials and the cost of bringing something to market.
The field of diagnostic applications of spectroscopy could potentially learn from the
successes and failures of other technologies in the clinical field and engaging with large
transnational organisations such as the European Clinical Research Infrastructures Network
(ECRIN - http://www.ecrin.org/) may help guide the strategic development.
Funding is limited to translate and develop technologies across the so called ‘valley of death’
to full in vivo clinical studies and implementation. Financing of development on such a scale
would require the support and commitment of National and International funders, the
medical community, instrument manufacturers and private funders. In order to justify
substantial funding, Health Economics need to be more critically explored and addressed,
and realistic business plans composed. In this context, identification of strategic target
applications may be crucial.
There is also a need to raise awareness of optical diagnostics within, and better engage, the
medical community, through conferences like SPEC. This includes surgeons, oncologists,
medical physics, Chief Executives of hospitals for local implementation, national boards e.g.
NICE in UK. This can be done through personal/local contacts, but also through
advertisement in relevant clinical publications. There is a need to create curiosity and
demand among the clinical community, but the talks at SPEC can be technically detailed and
inaccessible for clinicians. It is important to adopt clinical language: power analysis,
sensitivity/specificity, ROCs, patient benefit. Presentations need to be applications focused
and clinical sessions should be held at the weekend to facilitate attendance by medical
professionals. Open, targeted discussions with clinicians are essential such that practitioners

from various clinical backgrounds can present their work, the current state of the art and
the challenges faced, and that researchers can propose what spectroscopy has to offer in
relation to their clinical needs and how it relates to their approaches. There is a need to
educate the community better in the technologies of optical/spectroscopic diagnostics and
data analysis. This is a current need, but successful translation of the technologies will also
create a need for training at medical school level. An accessible handbook on optical
diagnostics for various clinical specialities could be valuable as an introduction to the field.
It is equally important to increasingly publish clinically relevant spectroscopic studies in
clinical journals and to promote the technologies at clinical conferences and at large medical
diagnostics exhibitions. Early adopters from the clinical community can help in this context,
and also to develop relationships with key thought leaders in the field and further promote
adoption of the technologies within their clinical communities. Where clinical trials have
been carried out, patients are powerful advocacy groups!
The research community should also seek publicity for their results using public and social
media wherever/whenever possible.
(ii)

Ex vivo tissue biopsies, body fluids and cytological samples for diagnostics and
disease studies

For the purposes of this discussion, Ex vivo applications of Vibrational spectroscopy are
interpreted to include analyses of samples taken directly from the body for diagnostic
purposes, namely tissue biopsies, cytological samples and body fluids.
From a surgical point of view, an alternative to in vivo spectroscopic monitoring would be
“near patient” screening of tissue biopsies taken intra-operatively to guide the surgeon in
identifying tumour margins. Ideally, analysis should be performed on fresh tissue, and

screening time, including data processing, should be kept to a minimum. As in the case of in
vivo measurement, time is of the essence, and so a fast, simple spectroscopic modality,
which is cheaper, more cost effective but has lower sensitivity and specificity may be a
viable solution.
However, there is a lack of concrete understanding of issues such as: What is the
competition? How much better can spectroscopy be? Within what reasonable timeframe
for measurement? The measurements should take a matter of minutes otherwise their
clinical utility will be questionable. Surgeons cannot afford to wait.
Such demands of speed of acquisition and data processing are considerably eased in
applications for histological screening, although it is recognised that current
mapping/imaging times of large areas of tissue followed by current pre- and post- data
processing protocols need to be improved [13], and, although significant progress has been
made, there is much to be done in terms of standardising procedures and protocols.
The demands on the ability to rapidly scan large areas of tissue probably currently favour
the use of FTIR rather than Raman spectroscopy for such applications.
In terms of sample presentation, fresh frozen sections are recommended as the tissue
architecture and biochemistry is kept largely intact and, notably, the lipidic information can
be

accessed

[14].

Furthermore,

they

are

more

amenable

to

combining

immunohistochemistry, proteomics, and biospectroscopy. However, clinically, fresh tissue is
normally only used for intraoperative work and stained, fixed sections are preferred for
histopathology [15]. Therefore, standardised protocols for spectroscopic analysis of
Formalin Fixed Paraffin Processed (FFPP) tissue sample are of paramount importance.

Notably, analyses of archived tissue libraries may add much to understanding disease
progression and patient prognosis.
It has been demonstrated that it is not necessary to remove the paraffin to obtain usable
spectral information, particularly in the case of FTIR spectroscopy [16]. Standard tissue
microarray protocols involve paraffin embedded tissue. Leaving the paraffin in place
reduces scattering artefacts and effects of further variable removal of aromatic solvent
soluble components. However, it may be argued that greater consistency of spectral
information is achieved when sections are deparaffinised. Deparaffinising also allows poststaining of the sections, although it has been demonstrated that the efficiency of the
deparaffinisation process can depend on the tissue pathology [17]. Nevertheless, even for
research purposes, protocols for such tissue processing should be maintained as close as
possible to those currently employed in the clinical environment.
In the case of FTIR based spectro-histopathology, there remains much debate on the
questions of measurement geometry, and therefore optimum choice of substrates. In terms
of cost, low-E, reflective slides appear most attractive, implying the use of a transflection
measurement configuration. However, questions have been raised concerning additional
spectral artefacts which can result from the so called “Electric Field Standing Wave” effect in
such measurements [18], although it has been argued that the effects are diminished by
thickness inhomogeneities, the range of sampling angles, and the source incoherence [19].
The alternative, transmission, geometry requires (at least partially) transparent substrates.
It has been demonstrated that even glass substrates may provide transmission in a
sufficiently broad (high wavenumber) region to provide diagnostic capabilities [20].

However, access to the broader spectrum is only provided by more costly polycrystalline
substrates such as CaF2.
Choice of substrate may ultimately be dictated by cost, and therefore by sample
throughput, and therefore by the target application. A full cost analysis is required to assess
the relative demand and costs of applications for (i) near patient intra operative diagnostic
(ii) postoperative histological and (iii) research purposes.
Cytological screening is commonly employed as a routine preventative measure or for early
stage disease detection, notably for cervical and oral disease. In the case of cervical,
screening programmes are well established in the “third world” and so sample throughput is
very high. This puts increased demands on the cost effectiveness of alternatives to currently
employed clinical practice.
Cervical screening is traditionally performed by the Pap smear methods, or more recently by
liquid based methods such as Sure-Path or Thin-Prep. In all cases, the samples are stained by
a combination of dyes. The Pap Smear test is reported to provide a sensitivity of ~72% and
specificity of ~94% [21]. Studies of the accuracy of liquid based monolayer cytology report
sensitivity of ~ 63% and specificity ~85% [21, 22]. The aetiology of the disease in the case of
cervical is predominantly linked with HPV infection, and so screening for HPV infection has
become increasingly popular, although, as it is more costly the procedure is most often used
as a further screen of suspicious cytological tests. Studies of the accuracy of HPV testing
report a sensitivity of ~90% and a specificity of ~ 80% [22, 23].
The use of vibrational spectroscopy as an adjunct or alternative to currently employed
cytological screening methods may be a viable strategic target objective. Sensitivities and
specificities of >90% as well as sensitivity to HPV infection have been reported [24, 25].

The use of glass slides for high throughput in all current clinical practices, as well as the
smaller spotsize/higher spatial resolution may favour the use of Raman spectroscopy in this
case. Raman can potentially selectively target either cell nuclear or cytoplasmic regions,
although the denser nuclear region provides greater diagnostic potential. In development of
Raman protocols, choice of wavelength is intimately linked with choice of substrate, and it
has been demonstrated that although conventional glass microscope slides have a
substantial background at 785nm, this is greatly reduced at 532nm [26].
In unstained cytological samples, 532nm causes negligible observable damage to the
samples over the measurement period. However, photodamage due to absorption and/or
large fluorescent backgrounds due to clinical stains presents a significant problem for the
use of Raman spectroscopy as an adjunct to cytological screening. Stained samples cannot
be simultaneously optically and spectroscopically screened [27], suggesting that a fully
automated procedure for unstained cell recognition, spectral analysis and assessment may
be required.
Screening of bodily fluids is a further ex-vivo application which is currently attracting
increasing attention and may represent a strategic, achievable target [28]. Suspended or
dissolved analytes are present in rather low concentrations, however, and many studies to
date have been performed on dried samples [29, 30]. The analysis of such samples can
suffer from problems associated with the chemical and physical inhomogeneity of the
deposit, reducing reproducibility and sensitivities. Bulk ATR FTIR measurements have been
shown to reduce such effects [31], however, and multi-well ATR devices have been
proposed to potentially offer high throughput screening.

Concentration of samples using centrifugal filtration devices has been shown to offer an
alternative which allows measurement of the analytes in the native aqueous environment.
Although Raman appears most promising in this context, due to the relatively lower
contribution of the water, sufficient concentration of the sample also allows analysis of the
fingerprint region by FTIR [32]. Centrifugal filtration also allows fractionation according to
molecular weight of the constituent analytes, potentially allowing targeting of molecular
biomarkers of disease [33]
As for the case of in vivo applications, translation of technologies to clinical practise will be
critically dependent on large scale studies with clinically relevant statistics. Diagnostic
applications rely heavily on multivariate statistical classification methodologies and each
analytical protocol must be “trained” For each potential application, the data can be
influenced by instrument, sample presentation and preparation, measurement protocol and
data processing. It is critical therefore that consensus be reached on Standard Operating
Procedures, to include all of these variables. Inter-laboratory and even inter- instrument
consistency and transferability needs to be established. Only then can large data bases be
established both for translational and research purposes.
There is also a need for extensive validation and prospective testing of data preprocessing
protocols as well as classification and regression models. In this context, using patient data,
it is impossible to know what is the “correct” result. Simulated data sets could play a key
role in validating data pre- processing methodologies, ensuring that the spectral integrity is
preserved [34, 35]. However, while they can play a similar role in validating classification
algorithms, correlation with disease pathology and patient prognosis still relies on

consensus clinical standards. The use of archived tissue banks for retrospective studies may
play a critical role in establishing such a clear correlation.
There is much scope for instrumental development, in collaboration with the instrument
companies. Ideally, instrumentation should be optimised for the specific purpose, ultimately
of automated ex-vivo screening of histological, cytological or biofluidic samples. However,
clinicians may be adverse to automated decision systems, and that they need to be the
ultimate arbiters. There may also be a disadvantage in some biophotonic-based diagnostics,
as they do not generate a consumable market, and thus it may be more difficult to garner
support from some companies. Much progress has, however, been made in the continued
development of portable devices, particularly in the case of Raman. This may generate
specific applications for example in contamination-restricted environments, and particularly
in field clinics.
(iii)

In vitro cell culture and 3D models for Research and Medical applications

The definition of “ex-vivo” to include tissue biopsies, cytological samples and biofluids
directly from the patient for diagnostic purposes restricts the discussion of “in vitro” to cell
culture models for both research and medical applications. As such, direct clinical
translation is probably limited, but, nevertheless, such models can prove invaluable for the
development and validation new measurement technologies, measurement and data
processing and analysis protocols, and ultimately the exploration of the limits of the
techniques in identifying and screening biomarkers associated with biological function and
dysfunction. The techniques may also provide valuable information on, for example,
radiation and chemotherapeutic resistance, and present opportunities in their own right for
potential applications in screening for drug delivery mechanisms and efficacy, radiation

damage and toxicology [36-38], given the drive for a reduction in the use of animal models
for evaluating toxicity, due to regulatory developments in both the EU and US (EU Directive2010/63/EU and US Public Law 106-545, 2010, 106th Congress) generally based on the
principle of the 3 R’s, to replace, reduce and refine the use of animals used for scientific
purposes. Therefore, there is currently much promotion of the development of in vitro
models which can accurately infer in vivo results.
In terms of basic research tools, the imperative for standardisation of measurement
protocols is not as urgent. Nevertheless, it is important that the spectral data acquired is
representative of the biochemical profile of the sample and free of “spectral artefacts”
which may arise from the measurement geometry, substrate, or sample. Much has been
achieved over the past decade to understand such artefacts [39, 40], but there remain
significant issues to be addressed. Ultimately, for successful application for in vitro drug or
toxicity screening, standard operating procedures will be required.
In the case of Infrared spectroscopy, the debate over the choice of measurement geometry
and hence choice of substrate is (at least) as relevant for analysis in vitro as it is for
diagnostics ex vivo. The transflection geometry appears to maximise both multiple beam
interference (e.g. EFSW) and scattering effects [18, 40], although neither are completely
absent in the transmission geometry. The severity of both is dependent on the homogeneity
of the sample, although algorithms for the removal of resonance scattering/reflection are
well established [34]. In the research environment, cost is less of a consideration that for
high throughput routine clinical screening and so, where possible the use of the more
expensive polycrystalline substrates (e.g. CaF2), in the transmission geometry, are
recommended. Notably, UV grade CaF2 is also an optimum substrate for Raman

measurement [26]. Measurement using ATR minimises (although does not completely
eradicate) scattering artefacts and has been gaining increased popularity, although the
sampling depth is limited.
In the case of Raman spectroscopy, most instrumentation operates in a back scattering
(microscopic) geometry, and consideration of the influence of substrate depends on sample
thickness and focal depth of the objective employed, and where substrate contributions are
significant, they depend on the source wavelength. Glass substrates have been shown to be
acceptable at visible wavelengths. Although they can contribute in the case of thin samples
(e.g. cytoplasm) the contribution can be removed by careful preprocessing. In the near
infrared, common microscope slides contribute a strong background which can completely
obscure the sample response, and normally quartz or ideally UV grade CaF2 is preferable
[26].
In terms of sample preparation/presentation, it is well accepted that measurement of live
cells is most desirable. In the case of infrared spectroscopy, the strong absorption of the
water bands in the region of ~1600cm-1 and 3300cm-1 presents a problem, although it
should be stressed that this does not prohibit measurement of live cells (or other aqueous
based biological samples) [41, 32]. Specifically designed sample compartments can minimise
the extracellular pathlength and the use of ultrabright synchrotron sources significantly
improve signal to noise [41]. In Raman spectroscopy, contributions from water are less of a
consideration and live cell imaging in buffer of complete cell culture medium has been
demonstrated [42]. It is important to note that, although the signal is small, water does
contribute to the underlying background and careful preprocessing of the data is essential,
remembering that water is also a constituent intracellular component.

In both cases, given current technologies, particularly in the case of Raman, whole cell
studies at high spatial resolution can be protracted and, to avoid bacterial contamination,
cell movement in the liquid environment, etc., it may be more advantageous to fix the cells
before measurement. A number of studies have demonstrated that formalin fixation best,
although not completely, preserves the biochemical integrity of the cells [43].
Commercial tissue models, notably for skin, are available and can aid in research purposes.
These can be measured “live”, or can be processed as normal tissue. They reduce sample
variability compared to human or animal samples and can be employed to optimize
measurement protocols, although it should be emphasized they are not exact replicas.
Notably, in the case of skin models, the basal layer is lacking in melanin, and also the lipidic
architecture of the stratum corneum does not well reproduce the barrier function of real
skin, limiting the suitability for perfusion studies [44].
Notably, it has been increasingly argued that 2D cell cultures are a poor representation of
the cellular environment in vivo, and that true cell morphology and cell behaviours, such as
drug uptake and response, would be much more closely mimicked in 3-D cell matrices. The
use of such constructs may also help to better understand cell/microenvironment
interactions and analysis of single cells in such environments seems to partly circumvent the
scattering issues which contribute to scattering backgrounds in both FTIR and Raman since
cells are no longer isolated.
Independent of use in spectroscopic research, it is important to develop and optimise these
models. In doing so, it is important to note that the diffusion and bioaviability of both
cytotoxicological assays and test substances in 3D matrices must be considered and
adaption of the protocols is necessary for direct comparison with the traditional 2D models

[45]. Nevertheless, such models represent an exciting new development for in vitro models
which better mimic in vivo conditions, and the emergence of IR tomographic image
reconstruction using synchrotron sources to image these structures holds great promise
[46]. The usefulness of Raman microspectroscopy "optical sectioning" should also be
emphasised.
Whereas diagnostic applications rely largely on classification or regression algorithms, in
vitro applications can potentially exploit the full analytical capabilities of biospectroscopy. In
this context, maintaining the integrity of the spectral information during data processing is
imperative. As in the case of ex vivo measurements, data preprocessing methodologies can,
and should, be validated using simulated datasets. Ideally, such data sets should include
spectral variability due to all potentially confounding experimental factors, as limits of
detection may ultimately be determined by such factors [47].
Postprocessing and analysis protocols can similarly be validated and optimised to ensure
that they produce the correct result [33, 35]. Simulated datasets, can be employed to
explore and develop the limits of biospectroscopy as an analytical technique, for example to
minimise the limits of detection of and maximise the specificity of regression algorithms and
feature selection based on spectral biomarkers [47]. With properly validated analytical
techniques, biospectroscopy could aspire to realisation of its potential as a truly label free,
high content screening technique based on the field of “specral-ohmics”.
Achieving such goals, as well as those of clinical translation, relies much on continued
instrumental development. Increased signal throughput and novel sampling techniques,
such as those afforded by Quantum Cascade Lasers in IR [48, 49, 50] and Bragg filters in
Raman [51] may significantly reduce sampling times over large areas. Emerging technologies

such as Surface Enhanced, Stimulated and Coherent Anti-Stokes Raman Spectroscopy may
similarly impact on sensitivity of data collection [52]. Atomic Force Microscopy- IR (AFMIR)
and Tip enhanced Raman Spectroscopy open up the realm of nanospectroscopy for both IR
and Raman spectroscopy. At present, at least, these developments are very much in the
research domain, however, and are most applicable to in vitro studies.
Summary
There are clearly many challenges facing the field of diagnostic applications of vibrational
spectroscopy. Many of these require a more significant engagement between the broad
range of stakeholders, from academic research scientists to clinical practitioners, and
including medical and spectroscopic instrument manufacturers.
Raising awareness of the field amongst the medical community can be achieved by
academic researchers by targeting medical journals and conferences, and similarly targeted
series of conferences can play a pivotal role in bringing the communities together.
In the move towards establishing and promoting SOPs, for measurement and data handling
protocols, national and international research networks such as the UK EPSRC Network
CLIRSPEC

(www.clirspec.org)

and

the

EU

COST

(http://www.cost.eu/domains_actions/bmbs/Actions/BM1401)

Action
can

Raman4Clinics

potentially

make

significant headway. Such networks can also address the question of what constitutes
robust statistics, to take account of population variance rather than simply technical
variance, blinded trials etc., and these should be expressed in terms of clinical language to
encourage clinical acceptance.
Ultimately, however, more targeted engagement with the medical community must be
undertaken to establish strategic target applications and performance levels for Minimal

Viable Solutions. Notably, substantial funding will be required to conduct large scale multilab and instrument inter-comparisons and ultimately clinical trials.
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